Trial · NCT04138277
Results by group126
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 126
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs Leading to Discontinuation of Study Drug | Treatment Continued Group | Subjects with TEAEs | 80 | Participants | |
| Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs Leading to Discontinuation of Study Drug | Treatment Switched Group | Subjects with TEAEs | 37 | Participants | |
| Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs Leading to Discontinuation of Study Drug | Treatment Continued Group | Subjects with TESAEs | 17 | Participants | |
| Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs Leading to Discontinuation of Study Drug | Treatment Switched Group | Subjects with TESAEs | 10 | Participants | |
| Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs Leading to Discontinuation of Study Drug | Treatment Continued Group | Subjects with TEAEs leading to discontinuation | 6 | Participants | |
| Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs Leading to Discontinuation of Study Drug | Treatment Switched Group | Subjects with TEAEs leading to discontinuation | 2 | Participants | |
| Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs Leading to Discontinuation of Study Drug | Treatment Continued Group | Subjects with TEAE leading to death | 1 | Participants | |
| Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs Leading to Discontinuation of Study Drug | Treatment Switched Group | Subjects with TEAE leading to death | 0 | Participants | |
| Change From Baseline in 6-Minute Walk Distance (6MWD) | Treatment Continued Group | -33.3 | Standard Deviation 37.60 | meters | |
| Change From Baseline in 6-Minute Walk Distance (6MWD) | Treatment Switched Group | -8.6 | Standard Deviation 62.77 | meters | |
| Change From Baseline in Sitting % Predicted Forced Vital Capacity (FVC) | Treatment Continued Group | -3.8 | Standard Deviation 9.10 | percent predicted FVC | |
| Change From Baseline in Sitting % Predicted Forced Vital Capacity (FVC) | Treatment Switched Group | -0.5 | Standard Deviation 8.54 | percent predicted FVC | |
| Change From Baseline in Manual Muscle Testing (MMT) Lower Extremity Score | Treatment Continued Group | 0.6 | Standard Deviation 4.38 | score on a scale | |
| Change From Baseline in Manual Muscle Testing (MMT) Lower Extremity Score | Treatment Switched Group | 0.4 | Standard Deviation 2.61 | score on a scale | |
| Change From Baseline in the Total Score for Patient-reported Outcomes Measurement Information System (PROMIS®) - Physical Function | Treatment Continued Group | -2.7 | Standard Deviation 8.38 | score on a scale | |
| Change From Baseline in the Total Score for Patient-reported Outcomes Measurement Information System (PROMIS®) - Physical Function | Treatment Switched Group | -2.5 | Standard Deviation 6.14 | score on a scale | |
| Change From Baseline in the Total Score for PROMIS® - Fatigue | Treatment Continued Group | 1.5 | Standard Deviation 7.14 | score on a scale | |
| Change From Baseline in the Total Score for PROMIS® - Fatigue | Treatment Switched Group | 1.1 | Standard Deviation 3.72 | score on a scale | |
| Change From Baseline in Gait, Stairs, Gower, Chair (GSGC) Test | Treatment Continued Group | 0.5 | Standard Deviation 2.98 | score on a scale | |
| Change From Baseline in Gait, Stairs, Gower, Chair (GSGC) Test | Treatment Switched Group | 0.3 | Standard Deviation 1.59 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04138277/results